Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 65, Issue 2, Pages 439-450
Publisher
Wiley
Online
2016-10-22
DOI
10.1002/hep.28877
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons
- (2016) Frederick C. Lahser et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection
- (2015) Anita Kohli et al. ANNALS OF INTERNAL MEDICINE
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens
- (2015) Eleanor M. Wilson et al. CLINICAL INFECTIOUS DISEASES
- Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.
- (2015) Maria Buti et al. CLINICAL INFECTIOUS DISEASES
- O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
- (2015) H. Dvory-Sobol et al. JOURNAL OF HEPATOLOGY
- O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
- (2015) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2015
- (2015) JOURNAL OF HEPATOLOGY
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
- (2015) Xavier Forns et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
- (2015) Mark Sulkowski et al. LANCET
- Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
- (2015) Anita Kohli et al. LANCET
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
- (2015) David Roth et al. LANCET
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
- (2015) Jürgen K Rockstroh et al. Lancet HIV
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now